The average one-year price target for Immix Biopharma (NasdaqCM:IMMX) has been revised to $16.66 / share. This is an increase of 25.64% from the prior estimate of $13.26 dated February 21, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $12.12 to a high of $24.15 / share. The average price target represents an increase of 91.05% from the latest reported closing price of $8.72 / share.
What is the Fund Sentiment?
There are 68 funds or institutions reporting positions in Immix Biopharma. This is an increase of 25 owner(s) or 58.14% in the last quarter. Average portfolio weight of all funds dedicated to IMMX is 0.13%, an increase of 347.49%. Total shares owned by institutions increased in the last three months by 710.97% to 24,393K shares. 
The put/call ratio of IMMX is 0.35, indicating a bullish outlook.
What are Other Shareholders Doing?
Janus Henderson Group holds 3,922K shares representing 7.44% ownership of the company.
Saturn V Capital Management holds 2,999K shares representing 5.69% ownership of the company.
Eventide Asset Management holds 2,549K shares representing 4.84% ownership of the company.
Marshall Wace, Llp holds 1,979K shares representing 3.76% ownership of the company. In its prior filing, the firm reported owning 55K shares , representing an increase of 97.22%. The firm increased its portfolio allocation in IMMX by 7,975.60% over the last quarter.
Millennium Management holds 1,660K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
